Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

HLTH INVESTORS NOTICE: Lieff Cabraser Reminds Nobilis Investors of Deadline in Securities Class Action

N.HLTH

The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the upcoming deadline to move for appointment as lead plaintiff in securities class litigation brought on behalf of investors who purchased or otherwise acquired the securities of Nobilis Health Corp. (“Nobilis” or the “Company”) (NYSE: HLTH) between April 2, 2015 and October 8, 2015, inclusive (the “Class Period”).

If you purchased or otherwise acquired the securities of Nobilis during the Class Period, you may move the Court for appointment as lead plaintiff by no later than December 21, 2015. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the action will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the action.

Nobilis investors who wish to learn more about the action and how to seek appointment as lead plaintiff should click here or contact Sharon M. Lee of Lieff Cabraser toll-free at 1-800-541-7358.

The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements and failed to disclose that: (i) Nobilis’s AccuraScope procedure, a purportedly minimally invasive spine surgery, lacked recognition from any university, medical body, or insurance company; (ii) the Company had overstated its 2014 revenues by as much as $36 million; and (iii) consequently, the Company had misrepresented its 2014 revenue growth rate as 161%, when it was actually only 44%.

On October 9, 2015, Seeking Alpha published an article describing the AccuraScope procedure’s “questionable insurability, unsubstantiated success rates, [and] lack of recognition from” universities, medical bodies, and insurance companies. The article additionally noted significant accounting red flags at Nobilis and reported that Nobilis had overstated its 2014 revenues by as much as $36 million. On this news, the price of Nobilis common stock fell $1.42 per share, or 27% from its closing price of $5.24 on October 8, 2015 to close at $3.82 per share on October 9, 2015, on extremely heavy trading volume.

About Lieff Cabraser

Lieff Cabraser Heimann & Bernstein, LLP is a nationally recognized law firm committed to advancing investor rights and promoting corporate responsibility.

For twelve years, the National Law Journal has selected Lieff Cabraser as one of the top plaintiffs’ law firms in the nation. Best Lawyers and U.S. News have also named Lieff Cabraser as a “Law Firm of the Year” each year the publications have given this award to law firms, including in 2015.

For more information about Lieff Cabraser and the firm’s representation of investors, please visit http://www.lieffcabraser.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Source/Contact for Media Inquiries Only:
Lieff Cabraser Heimann & Bernstein, LLP
Sharon M. Lee, 800-541-7358